Literature DB >> 2226501

In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

A Huang1, F Edwards, E M Bernard, D Armstrong, H J Schmitt.   

Abstract

The in vitro activity of cilofungin (LY121019), a new semi-synthetic antifungal agent was evaluated. Potent activity was seen against Candida albicans and Candida tropicalis, with almost identical MIC and MFC results, whereas no activity was seen against any isolates of Candida parapsilosis or three Aspergillus spp. However, MICs were dependent on medium and test conditions chosen. It is concluded that cilofungin has good activity against some medically important yeasts in vitro, and that its in vitro activity depends on the method used.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2226501     DOI： 10.1007/bf01964276

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  13 in total

Review 1.  Testing of organisms for susceptibility to triazoles: is it justified?

Authors:  G S Kobayashi; E D Spitzer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

2.  Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.

Authors:  C J Morrison; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts.

Authors:  B C Baguley; G Römmele; J Gruner; W Wehrli
Journal:  Eur J Biochem       Date:  1979-07

4.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

6.  Treatment of experimental disseminated candidiasis with cilofungin.

Authors:  J R Perfect; M M Hobbs; K A Wright; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

Authors:  R Horn; B Wong; T E Kiehn; D Armstrong
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

8.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

9.  Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; A Maksymiuk; M Keating; K B McCredie
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

10.  Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans.

Authors:  M Pfaller; J Riley; T Koerner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267
View more
  10 in total

1.  Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Authors:  M S Rouse; B M Tallan; J M Steckelberg; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

5.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Genetic modification of an echinocandin B-producing strain of Aspergillus nidulans to produce mutants blocked in sterigmatocystin biosynthesis.

Authors:  R L Hodges; D W Hodges; K Goggans; X Xuei; P Skatrud; D McGilvray
Journal:  J Ind Microbiol       Date:  1994-11

9.  In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

Authors:  K Bartizal; T Scott; G K Abruzzo; C J Gill; C Pacholok; L Lynch; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

10.  Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

Authors:  M B Kurtz; E M Bernard; F F Edwards; J A Marrinan; J Dropinski; C M Douglas; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.